Obesity is a growing concern across geographies and it is not limited to people who are past their teenage. About two to six percent of obese individuals generate the signs of overweightness even as a child and it is connected to their genes. Termed as monogenic obesity, these individuals have a metabolism and an appetite for hunger that overrules their feeling of satisfaction from food. Additionally, commonly available treatment methods have little effect on these individuals who are born with an exceptional bon appetit.
Recently, researchers from the University of Copenhagen have detected that these people with monogenic obesity can overcome the disorder via their medicine liraglutide, which essentially is an upgraded formulation of appetite-inhibiting hormone GLP-1. According to the lead researcher, these group of people are born with a program to eat and gain weight, but their new drug can help in reducing the feeling of hunger.
The research program analyzed 14 obese individuals who had gained the disorder via pathogenic mutations and 28 of those who didn’t. The two groups were subjected to the medicine for an observation period of four months but no alterations were made to their daily exercise regime or their diet. It was observed that those cases with monogenic obesity lost nearly seven kilograms of weight whereas those with common obesity lost about six kilograms.
The medicine acts as a linear GLP-1 hormone which is preset within us, and has had approvals from the European Medical Association and Food and Drug Administration in the U.S.